Company news
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY) news
Dr. Reddy's Laboratories Ltd. news releases on 6ix. Latest, Oct 7, 2026: Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release…
Press releases & updates
Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated October 07, 2026, titled "Intimation of Earnings call".
October 7, 2026
Dr. Reddy’s Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States
August 4, 2026
Dr. Reddy's Laboratories Ltd. Press Release Aug 01 2026
August 1, 2026
Dr. Reddy's Laboratories Ltd. Press Release Jul 23 2026
July 22, 2026
Dr. Reddy's Laboratories Ltd. Press Release Jul 13 2026
July 13, 2026
Dr. Reddy's Laboratories Limited Announces Filing of Annual Report on Form 20-F
June 29, 2026
Dr. Reddy’s Laboratories Limited Announces Filing of Annual Report on Form 20-F
June 26, 2026
Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States
June 13, 2026
Dr Reddy Laboratories : Annual Report for Fiscal Year Ending March 31, 2026 (Form 20-F)
May 29, 2026
Press Release May 28 2026
May 28, 2026
Dr. Reddy's Laboratories Launches its Generic Semaglutide Injection in Canada
May 16, 2026
Press Release May 16 2026
May 15, 2026
Press Release May 12 2026
May 12, 2026
Dr. Reddy's Laboratories Announces Health Canada Approval for Generic Semaglutide Injection in Canada
April 29, 2026
Press Release Apr 24 2026
April 24, 2026
Press Release Mar 21 2026
March 21, 2026
Dr. Reddy's Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept
February 23, 2026
Dr. Reddy’s Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept
February 20, 2026
Press Release Feb 18 2026
February 18, 2026
Coya Therapeutics Announces $11.1 Million Private Placement
January 30, 2026
Dr Reddy Laboratories : . Reddy’s Q3 & 9MFY26 Financial Results
January 21, 2026
Dr. Reddy's announces the first-to-market launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7%, the generic equivalent of Extra-Strength Pataday Once Daily Relief, in the U.S.
January 15, 2026
Press Release Jan 14 2026
January 14, 2026
Dr. Reddy’s Announces the First-to-Market Launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the Generic Equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S.
January 14, 2026
Press Release Jan 08 2026
January 8, 2026
Press Release Dec 12 2025
December 12, 2025
Dr. Reddy's Laboratories Ltd. Press Release Dec 12 2025
December 11, 2025
Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS
December 9, 2025
Immutep and Dr. Reddy’s enters into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa
December 8, 2025
Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies
December 2, 2025
Press Release Nov 24 2025
November 24, 2025
Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update
November 12, 2025
Esperion Reports Third Quarter 2025 Financial Results and Provides Business Update
November 6, 2025
Aurigene Oncology to Showcase Innovative A-PROX Platform at the AACR-NCI-EORTC International Conference 2025
October 22, 2025
Press Release Oct 13 2025
October 13, 2025
Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy’s Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040
October 3, 2025
Press Release Sep 16 2025
September 16, 2025
Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
August 25, 2025
Extrovis AG and Dr. Reddy’s announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S.
August 18, 2025
Press Release Jul 23 2025
July 23, 2025
Dr. Reddy’s Q1FY26 Financial Results
July 23, 2025
Cenra Healthcare and Dr. Reddy's Strengthen Strategic Partnership to Expand Access to Medicines in Taiwan
July 21, 2025
Press Release Jul 15 2025
July 15, 2025
Press Release Jun 05 2025
June 5, 2025
Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)
June 5, 2025
Dr. Reddy's Laboratories Ltd. Press Release Jun 05 2025
June 4, 2025
Dr. Reddy’s Q4 & Full Year FY25 Financial Results
May 9, 2025
Press Release Apr 24 2025
April 24, 2025
Alvotech and Dr. Reddy’s Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
March 18, 2025
Press Release Mar 13 2025
March 13, 2025